PGDx Launches CancerSelect™ ES Providing Turnkey Solution
Complete the form below to unlock access to ALL audio articles.
Personal Genome Diagnostics Inc. (PGDx) has announced the launch of its CancerSelect™ Enterprise Solution (ES) that enables laboratories with next-generation sequencing capability to conduct advanced cancer genetic testing for research applications.
CancerSelect ES provides a turnkey solution that includes CancerSelect gene panels, proprietary bioinformatics software, staff training, ongoing technical support, report generation, and panel updates. The two PGDx CancerSelect panels detect alterations in 88 and 203 well-characterized genes that are of high biologic importance in cancer. They have been selected for their relevance to cancer-related drug targets and pathways.
The CancerSelect gene panels identify genetic alterations in the targeted genes, including point mutations, copy number alterations and genetic rearrangements. Most other cancer gene tests only identify point mutations, yet all three types of genetic alterations can potentially play a role in disease progression and response to current or future therapies.
Antony Newton, Chief Commercial Officer at PGDx, commented, “CancerSelect ES reflects our commitment to using genetic information to advance cancer research with the goal of ultimately improving cancer therapy. We are packaging our deep technical and clinical know-how into a kit designed to enable laboratories with next-generation sequencing capability to provide high quality, advanced cancer testing for research applications, while minimizing expense and effort. The CancerSelect gene panels have been optimized to balance the value of the information obtained with the cost of running the test, and there are minimal upfront outlays needed. Our support team trains laboratory staff and provides ongoing technical assistance, and we will continue to update the gene panels as new information becomes available.”
The CancerSelect gene panels achieve analytical sensitivity of more than 99% for mutations and indels at 2% mutant allele frequency. Their specificity is greater than 99.99%, with a target depth of coverage of more than 1500. Test results can be generated in as little as two weeks.
Visit Booth #1223 at the Association for Molecular Pathology (AMP) 2014 Annual Meeting to learn more about CancerSelect ES. PGDx co-founders Victor Velculescu, MD, PhD, and Luis Diaz, MD, will be presenting at the AMP 2014 Symposium, Cell-free Circulating DNA for Diagnosis or Prognosis of Cancer, to be held on November 15, 2014 at 1:30pm ET. Dr. Velculescu will discuss Liquid Biopsy Approaches for Detecting and Characterizing Human Cancer and Dr. Diaz will discuss Clinical Applications of Liquid Biopsies.
The 2014 Annual Meeting of the Association for Molecular Pathology (AMP) is being held November 12-15, 2014 at the Gaylord National Resort & Convention Center, National Harbor, MD. For more information, visit www.amp.org/meetings/2014/.
